Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Increase in Short Interest

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the recipient of a large growth in short interest in February. As of February 13th, there was short interest totaling 55,692 shares, a growth of 245.0% from the January 29th total of 16,141 shares. Based on an average daily volume of 28,113 shares, the short-interest ratio is currently 2.0 days. Approximately 2.6% of the shares of the stock are sold short. Approximately 2.6% of the shares of the stock are sold short. Based on an average daily volume of 28,113 shares, the short-interest ratio is currently 2.0 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Wednesday, January 21st. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce”.

Xenetic Biosciences Price Performance

Shares of NASDAQ XBIO opened at $2.44 on Thursday. Xenetic Biosciences has a 1 year low of $1.90 and a 1 year high of $13.93. The stock has a market capitalization of $5.59 million, a P/E ratio of -1.19 and a beta of 2.29. The company’s 50-day moving average is $2.26 and its 200 day moving average is $2.88.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Xenetic Biosciences stock. Renaissance Technologies LLC grew its position in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 516.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 178,509 shares of the company’s stock after buying an additional 149,559 shares during the quarter. Renaissance Technologies LLC owned 7.80% of Xenetic Biosciences worth $387,000 as of its most recent filing with the Securities & Exchange Commission. 15.12% of the stock is currently owned by institutional investors.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.